Skip to main content
TipRanks
Go Ultimate75% OFF

AstraZeneca (AZN) Stock Price & Analysis

664 Followers

AZN Stock Chart & Stats

$184.45$0.07(0.04%)
At close: 4:00 PM EST
$160$170$180$190Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$183.93 - $186.15
52-Week Range
$153.41 - $212.71
Previous Close
$184.38
Volume
N/A
Average Volume (3M)
2.99M
Market Cap
$286.56B
Enterprise Value
$211.22B
Total Cash (Recent Filing)
$8.11B
Total Debt (Recent Filing)
$33.97B
Price to Earnings (P/E)
25.9
Beta
0.02
Next Earnings
Feb 11, 2027 (Est.)
Dividend Yield
1.75%

Bulls Say, Bears Say

Bulls Say

Broad Portfolio Growth

Growth across several major therapy areas and regions reduces reliance on any single medicine or market. This breadth supports more resilient revenue compounding, strengthens commercial scale, and provides a durable platform for absorbing weakness in mature products.

Deep Pipeline And Innovation

A large late-stage pipeline gives AstraZeneca multiple opportunities to replenish and expand its medicine portfolio as existing products mature. Repeated clinical and regulatory catalysts can extend growth, diversify future revenue, and reinforce its competitive position.

Strong Profitability And Balance Sheet

Improving margins and a growing equity base indicate substantial earnings power and financial resilience. Strong profitability can fund research, business development, and shareholder returns while helping the company support its broad innovation program over time.

Bears Say

Loss-of-exclusivity Pressure

Patent and biosimilar erosion is reducing revenue from important established medicines, creating a recurring replacement requirement for the pipeline. Continued generic competition can pressure growth and margins until newer launches become large enough to offset declines.

Mixed Cash Conversion

A meaningful gap between earnings and cash generation can constrain internally funded investment and shareholder returns if it persists. Lower operating cash flow despite higher earnings also increases reliance on working-capital normalization and disciplined cash management.

Restructuring And Investment Burden

Higher capital spending, deal-related payments, and restructuring costs will absorb cash while AstraZeneca continues investing heavily in research. Although intended benefits are substantial, execution over several years may pressure near-term margins and financial flexibility.

AstraZeneca News

AZN FAQ

What was AstraZeneca’s price range in the past 12 months?
AstraZeneca lowest stock price was $153.41 and its highest was $212.71 in the past 12 months.
What is AstraZeneca’s market cap?
AstraZeneca’s market cap is $286.56B.
When is AstraZeneca’s upcoming earnings report date?
AstraZeneca’s next earnings report is estimated for Feb 11, 2027 (not yet confirmed), which is in 87 days.
How were AstraZeneca’s earnings last quarter?
AstraZeneca released its earnings results on Oct 30, 2026. The company reported $2.79 earnings per share for the quarter, beating the consensus estimate of $2.586 by $0.204.
Is AstraZeneca overvalued?
According to Wall Street analysts AstraZeneca’s price is currently Undervalued.
Does AstraZeneca pay dividends?
AstraZeneca pays a semiannual dividend of $1.06 which represents an annual dividend yield of 1.75%. See more information on AstraZeneca dividends here
What is AstraZeneca’s EPS estimate?
AstraZeneca’s EPS estimate is 2.32.
How many shares outstanding does AstraZeneca have?
AstraZeneca has 1,551,065,200 shares outstanding.
What happened to AstraZeneca’s price movement after its last earnings report?
AstraZeneca reported an EPS of $2.79 in its last earnings report, beating expectations of $2.586. Following the earnings report the stock price went up 7.024%.
Which hedge fund is a major shareholder of AstraZeneca?
Currently, no hedge funds are holding shares in AZN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology